HIV Pre-exposure Prophylaxis and Buprenorphine at a Drug Detoxification Center During the Opioid Epidemic: Opportunities and Challenges
Authors:
- Sabrina A. AssoumouSASabrina A. Assoumou
- Samantha M. PaniaguaSPSamantha M. Paniagua
- Priscilla GonzalezPGPriscilla Gonzalez
- Jianing WangJWJianing Wang
- Curt G. BeckwithCBCurt G. Beckwith
- Laura F. WhiteLWLaura F. White
- Jessica L. TaylorJTJessica L. Taylor
- Kristen CooganKCKristen Coogan
- Jeffrey H. SametJSJeffrey H. Samet
- Benjamin P. LinasBLBenjamin P. Linas
- 22 March 2021
- journal article
- research article
- Published by Springer Nature in AIDS and Behavior
- Vol. 25 (8) , 2591-2598
Abstract
Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) and buprenorphine decrease HIV acquisition. Between November, 2016 and July, 2017, we surveyed persons (N = 200) at a drug detoxification center to assess their interest in PrEP and in buprenorphine, and to examine factors associated with such interests. Over the previous 6 months, 58% (117/200) injected drugs, 87% (173/200) used opioids, 50% (85/171) had condomless sex. Only 22% (26/117) of persons who injected drugs were aware of PrEP, yet 74% (86/116) and 72% (84/116) were interested in oral or injectable PrEP, respectively. Thirty-eight percent (47/125) of persons not receiving buprenorphine or methadone expressed interest in buprenorphine. After multivariable adjustment, Latinx ethnicity was associated with interest in PrEP (aOR 3.80; 95% CI 1.37–10.53), while male gender (aOR 2.76; 95% CI 1.21–6.34) was associated with interest in buprenorphine. Opportunities exist to implement PrEP and buprenorphine within drug detoxification centers. Clinical trial registration NCT02869776. Clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT02869776?term=Sabrina+Assoumou&cond=HIV+HCV&rank=1.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (P30AI042853)
- National Institute of Drug Abuse (R25DA035163, K23DA044085)
- National Institute of Drug Abuse (R01DA046527, P30DA040500)
This publication has 32 references indexed in Scilit:
- Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugsDrug and Alcohol Dependence, 2016
- Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2013
- Racial Differences and Correlates of Potential Adoption of Preexposure ProphylaxisJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- Opioid Agonist Treatments and Heroin Overdose Deaths in Baltimore, Maryland, 1995–2009American Journal of Public Health, 2013
- Collaborative Care of Opioid-Addicted Patients in Primary Care Using BuprenorphineArchives of internal medicine (1960), 2011
- Adoption and Implementation of Medications in Addiction Treatment ProgramsJournal of Addiction Medicine, 2011
- A Transitional Opioid Program to Engage Hospitalized Drug UsersJournal of General Internal Medicine, 2010
- Methadone maintenance therapy versus no opioid replacement therapy for opioid dependenceCochrane Database of Systematic Reviews, 2009
- Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviorsJournal of Substance Abuse Treatment, 2008
- Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and NaloxoneNew England Journal of Medicine, 2003